A phase IV, open-label, single-arm study in Caucasian NSCLC patients (N = 652) demonstrated 94% concordance for EGFR mutations detected (by ARMS, Qiagen) between plasma and tumor tissue in a study evaluating efficacy and safety of gefitinib [26]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.